News >

Benefit of Extended Adjuvant Endocrine Therapy Remains Unknown

Angelica Welch
Published: Monday, Oct 29, 2018

Melanie Majure, MD

Melanie Majure, MD
Patients with hormone receptor (HR)-positive breast cancer generally have a good prognosis, said Melanie Majure, MD. However, more work needs to be done since greater than 50% of patients’ disease recurs after 5 years, she added.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication